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Antimicrobial prophylaxis during surgery aims to prevent post-operative site infec-
tions. For fetal surgery, this includes the fetal and amniotic compartments. Both are
deep compartments as drug equilibrium with maternal blood is achieved relatively
late. Despite prophylaxis, chorio-amnionitis or endometritis following ex utero intra-
partum treatment or fetoscopy occur in 4.13% and 1.45% respectively of the
interventions.
This review summarizes the observations on two commonly administered antimicro-
bials (cefazolin, clindamycin) for surgical prophylaxis during pregnancy, with emphasis
on the deep compartments. For both compounds, antimicrobial exposure is on target
when we consider the maternal and fetal plasma compartment. In contrast, amniotic
fluid concentrations-time profiles display a delayed and much more blunted pattern,
behaving as deep compartment. For cefazolin, there are data that document further
dilution in the setting of polyhydramnios. Along this deep compartment concept,
there is some accumulation during repeated administration, modeled for cefazolin
and observed for clindamycin. The relative underexposure to antimicrobials in amni-
otic fluid may be reflected in the pattern of maternal-fetal complications after fetal
surgery, and suggest that antimicrobial prophylaxis practices for fetal surgery should
be reconsidered.
Further studies should be designed by a multidisciplinary team (fetal surgeons, clinical
pharmacologists and microbiologists) to facilitate efficient evaluation of antimicrobial
prophylaxis.
1 | INTRODUCTION
The purpose of antimicrobial prophylaxis during surgery is to minimize
colonization of micro-organisms at the surgical site(s) throughout the
procedure to minimize or prevent surgical site infections (SSI).1 The
antimicrobial (drug choice, dose selected) administered should hereby
ensure adequate serum and tissue (subcutaneous or other relevant
compartments) concentrations from incision, throughout, and until
shortly after surgery. This means that we should consider the micro-
organisms (Staphylococcus aureus as reference pathogen, but
coagulase-negative staphylococci [CoNS] may also be involved) rele-
vant to the site of surgery and their pharmacodynamic target.1,2
These general concepts obviously also apply for surgical interven-
tions during pregnancy, including fetal surgery. However, pregnancy-
related changes like the increase in glomerular filtration, cardiac
output and total body volume, changes in body composition and pro-
tein binding, as well as specific compartments of interest, like the fetal
compartment and amniotic cavity should be taken into account as
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these changes affect pharmacokinetics.2-5 These are deep compart-
ments, that is, body compartments where drug equilibrium is achieved
relatively late. As the data on time-concentrations profiles are limited,
other commonly performed surgical interventions provide at least
some information on the pharmacokinetics and target attainment in
some of the relevant compartments.
The most commonly performed surgical intervention during preg-
nancy is a cesarean section. In the Center for Disease Control (CDC)
2017 update on surgical prophylaxis, a clear position on the timing of
antimicrobial administration (before incision) was taken.1 When pro-
phylactic antibiotics (any time) were compared to no prophylaxis dur-
ing cesarean section, there was a significant reduction in the
incidence of wound infection (RR 0.40, 95% CI 0.36-0.46), endometri-
tis (RR 0.38, 95% CI 0.34-0.42) and other serious maternal infectious
complications (RR 0.31, 95% CI 0.20-0.49).6 Administration of antibi-
otics (eg, cefazolin, clindamycin) before skin incision in women under-
going cesarean section further reduced the risk of endometritis, and
also wound infection compared to those who received antibiotics
after neonatal cord clamping.1,7,8
The antibiotics commonly administered for surgical prophylaxis
do cross the placenta to result in fetal co-exposure.3,4,9 Within the
setting of prophylaxis for cesarean delivery, this is unintended but
there is evidence that this does not result in short-term adverse health
effects for the newborn. In contrast, there is still debate and an active
research line on the question if perinatal antimicrobial exposure mod-
ulates the long-term risks for allergy-related syndromes, like eczema,
asthma or auto-immune diseases, with alterations in the neonatal gut
microbiome as claimed mechanism.9
However, risk reduction does not imply that infections do not
occur. In the most recent Cochrane review on the impact of anti-
microbial prophylaxis on post-cesarean infections, the incidence
of maternal febrile morbidity, wound infection, endometritis and
other serious infectious complications were still 12,3%, 3.4%,
5.7% and 0.5% respectively in the prophylaxis group.6 In a recent
study comparing the rate of SSIs in women undergoing cesarean
delivery, cellulitis was more common in women exposed to
clindamycin + gentamicin (900 mg + 5 mg/kg) (adjusted odds ratio
1.93, 95% CI 1.03-3.31, 4.7 vs 2.4%) when compared to cefazolin
(2-3 g).10
Fetal surgery includes procedures on the umbilical cord, the pla-
centa or membranes, and/or the fetus with also relevant differences
in duration and extent or invasiveness of surgery. For fetal surgery,
commonly used dosing regimens for antimicrobial prophylaxis are
cefazolin, 2 g 8qh for 24 hours, or clindamycin, 900 mg 8qh for
24 hours, initiated “shortly” before surgery. Furthermore, some sur-
geons administer an additional dose (eg, cefazolin [500 mg], 600 mg
clindamycin [600 mg], 500 mg nafcillin [500 mg], vancomycin
[500 mg], ampicillin [4 g], oxacillin [400 mg]) in the amniotic cavity at
the end of more complex and prolonged fetal surgical procedures, like
fetal repair of spina bifida or fetal tumor resection.11,12
This review aims to summarize the observations on cefazolin and
clindamycin pharmacokinetics as most commonly administered anti-
microbials for prophylaxis during pregnancy, with specific emphasis
on the compartments relevant to fetal surgery (fetus and amniotic
cavity) to illustrate the fragmented and limited information. We briefly
introduce these compound specific findings by describing the impact
of pregnancy on the pharmacokinetics of antimicrobials. Following the
discussion of these compound specific findings (cefazolin,
clindamycin), we suggest a research approach and the available tools
to make progress in the field of antimicrobial prophylaxis for fetal
surgery.
1.1 | Pharmacokinetics of antimicrobials during
pregnancy
It is reasonable to assume similar antimicrobial pharmacodynamics
during pregnancy when compared to the non-pregnant setting.13
Related to these pharmacodynamics, three patterns for targeted and
effective pharmacotherapy have been defined, depending on the anti-
microbial mechanisms to attain maximal bacterial killing. These pat-
terns are either (i) the fraction of time (duration) that an antimicrobial
remains above a target minimal inhibitory concentration (MIC) thresh-
old (beta-lactams, including cefazolin), (ii) the peak antimicrobial con-
centration above a given concentration or (iii) a mix of both, with the
area under the concentration-time curve divided by a target (as for
vancomycin or clindamycin).13
What's already known about this topic?
• Various practices of antimicrobial prophylaxis during fetal
surgery have been reported.
• However, chorio-amnionitis or endometritis following ex
utero intrapartum treatment or fetoscopy occur in 4.13%
and 1.45% respectively of the interventions, without
available data on the most effective strategies for antimi-
crobial prophylaxis.
What does this study add?
• Based on limited data during fetal surgery,
concentrations-time profiles for cefazolin and
clindamycin in the maternal and fetal compartments are
on target, while these profiles in the amniotic fluid com-
partment display a delayed and more blunted pattern,
resulting in suboptimal amniotic exposure.
• This suggests that we should study these practices to
reconsider dosing regimens to potentially improve out-
comes. Such studies should be designed by a multi-
disciplinary team (fetal surgeons, clinical pharmacologists
and microbiologists) to facilitate efficient evaluation of
antimicrobial prophylaxis.
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Consequently, similar exposure of antibiotics should be aimed for,
integrating the pregnancy related aspects of pharmacokinetics in dosing
regimens. Many of the anatomic and physiologic changes observed dur-
ing pregnancy will result in marked changes in absorption, distribution,
metabolism and elimination (ADME), collectively referred to as pharma-
cokinetics. It is hereby important to stress that pregnancy is not a dichot-
omous factor, and that changes are not uniform, but evolve over the
consecutive trimesters of pregnancy. Some of these changes in maternal
physiology of relevance to PK of antimicrobials for the consecutive tri-
mesters of pregnancy are further illustrated in Figure 1.
As these antimicrobials are administered by the intravenous
route, absorption is only a marginal issue, although fetal absorption
from the amniotic cavity may also occur. Distribution during preg-
nancy can be influenced by changes in body weight, regional blood
flows, tissue composition (like body water, body fat), plasma composi-
tion and volume and alterations in the unbound fraction of a given
antimicrobial. Clearance is driven by metabolism and elimination, with
renal elimination (glomerular filtration, renal tubular transport) as the
main route of elimination for most antibiotics.4,5 The glomerular filtra-
tion rate increases significantly during pregnancy, predominantly as a
consequence of the increased renal blood flow and ultimately also
due to single nephron glomerular hyperfiltration (Figure 1).14 Finally,
the antimicrobials commonly used for prophylaxis do cross the pla-
centa, resulting in fetal co-exposure, with a given exposure over time.
This includes an equilibration half-life (describing the time lag)
between the maternal plasma and the fetal plasma and—when
applicable—amniotic cavity. The subsequent impact of these ADME
aspects for “model” compounds (cefazolin, clindamycin) will be dis-
cussed separately.
1.2 | Cefazolin
Compound and target: Cefazolin is a first generation cephalosporin for
intravenous or intramuscular administration. It is the most commonly
used prophylactic antimicrobial agent for surgery. For fetal surgery, a
commonly used dosing regimen is 2 g.q8h for 24 hours. The European
Committee on Antimicrobial Susceptibility testing (EUCAST) mentions
a MIC distribution of 0.125-2 mg/L and an epidemiological cutoff
(ECOFF) of 2 mg/L for S aureus.15 Consequently, the current minimal
targeted cefazolin MIC to treat or prevent S aureus infections is 2 mg/
L. Obviously, this ECOFF may change over time in the event of
emerging resistance.
Pharmacokinetics: Both non-compartmental and compartmental
pharmacokinetic (PK) analyses have been performed to describe
cefazolin PK in pregnant women, with a wide variety of tissues (eg,
blood, adipose tissue or both), drug concentrations (total, unbound or
both) and clinical characteristics (obese, non-obese, different gesta-
tional ages).16-18 For this compound, the two main pregnancy related
changes are the differences in glomerular filtration rate and in protein
binding (Figure 1).19
Cefazolin clearance of the maternal blood compartment during preg-
nancy is twice that of healthy young adults, while the equilibration half-life
between the plasma and amniotic fluid compartment is 4.4 hours.20
Maternal administration of 2 g of cefazolin results in therapeutic concen-
trations in umbilical cord blood at delivery (free cefazolin con-
centration > 8 mg/L) in the newborn for at least 5 hours after delivery,
with an equilibration half-life between mother and fetus of about
2 hours.17 A similar pattern on maternal-fetal exposure with fetal levels in
the therapeutic range has been described in case of maternal obesity.21
F IGURE 1 Percentage changes in physiologic parameters across the consecutive trimesters of pregnancy compared to the pre-pregnancy
setting (100%). Percent changes have been calculated at 12, 24 and 36 weeks based on the individual trend lines as described by Abduljalil et al
to reflect the first, second and third trimester. GFR, glomerular filtration rate5
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In contrast and following the first 2 g dose of cefazolin at the time
of fetal surgery (2 g.q8h, 24-48 hours) the median cefazolin concen-
tration in the amniotic fluid was 0.62 (n = 96 observations, range
0.06-3.73) mg/L. This dataset covers the full gestational age range of
relevance to fetal surgery from 17 weeks until term gestational age.
Within this age range, cefazolin clearance was not affected by gesta-
tional age. However, and of relevance to fetal surgery, in the presence
of polyhydramnios (caused by the fetal condition under study in that
case), these concentrations were even lower [(0.4 (range 0.12-0.6) vs
1.3 (0.06-3.9) mg/L in the absence of polyhydramnios)].20 In two of
these in utero interventions, fetal urine was simultaneously collected
as bladder puncture was part of the scheduled fetal intervention.20 In
both events, fetal urine cefazolin concentrations were significantly
higher compared to paired amniotic fluid observations: 1.94 and 5.5,
compared to 0.83 and 1.25 mg/L respectively illustrating the contri-
bution of fetal renal clearance to the amniotic cavity cefazolin concen-
trations. In another cohort of pregnant women at term (elective
cesarean, n = 18), the mean cefazolin concentration was 1.54
(SD 2.1) mg/L.22
Merging the available evidence, the amniotic cavity as deep com-
partment does not attain the target levels, while the fetal and mater-
nal blood compartments are above the minimal target. Pending on the
type of surgery, the antibiotic concentrations reached in the amniotic
fluid compartment are of particular interest for fetal surgeons as this
is the site where fetal surgery is performed, and inoculation of bacte-
ria may occur. This might be compensated by the practice to inject an
antibiotic in the amniotic cavity at the end of more complex and pro-
longed fetal surgical procedures, like fetal repair of spina bifida or fetal
tumors.11,12
Clinical practice and efficacy: Clinical practice guidelines based on
a review of the earlier mentioned PK evidence in maternal plasma and
subcutaneous tissue, and expert opinion recommend to increase the
single preoperative prophylactic dose (from 2 to 3 g) before cesarean
intervention in obese and morbidly obese patients, but this has not
been proven to be of additional benefit in different studies.1 In the
most recent study, La Rosa et al reported on a retrospective analysis
and observed an overall low (5%) incidence of SSI, without differences
for the higher dose (2 g when body mass index (BMI) <30, 3 g if
BMI≥30) vs the regular dose (1 and 2 g respectively) cohort.23 How-
ever, for non-elective (during labor or after membrane rupture) cesar-
ean delivery, extended-spectrum prophylaxis with adjuvant
azithromycin (500 mg, intravenous) in addition to “standard” cefazolin
dosing resulted in a significant reduction (12%-6.1%) of the composite
outcome (endometritis, wound infection or any other infection).24
There are no data specific on the association of cefazolin exposure
and maternal-fetal outcome after fetal surgery.
1.3 | Clindamycin
Compound and target: Clindamycin is a lincosamide antibiotic
approved for use in adults and children requiring treatment for staph-
ylococcal, streptococcal or anaerobic infections. Clindamycin binds to
the 50S bacterial ribosome subunit to inhibit protein synthesis. Con-
sequently, clindamycin has a bacteriostatic action. The EUCAST
ECOFF for S aureus is 0.25 mg/L, and for Streptococci spp. (including
group B Streptococcus) 0.25 or 0.5 mg/L. For gram-positive anaer-
obes or gram-negative anaerobes, a target value of 4 mg/L is used.15
Clindamycin efficacy hereby correlates to the area under the concen-
tration curve (AUC) for the free drug concentration divided by the
current MIC [fAUC0-24h/MIC].
3,25
Clindamycin is used to treat infections during pregnancy and its
systemic use was classified as Pregnancy category B drug in the for-
mer FDA classification (B = no risk in animal reproductive studies,
F IGURE 2 Pooled observations of
individual paired clindamycin
concentrations in maternal plasma (black
square) and umbilical cord blood (gray
triangle) after first intravenous
administration of 900 mg clindamycin to
the mother before delivery.25,31 X-
axis = time (minutes); Y-axis = clindamycin
concentration (mg/L)
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because studies in humans cannot rule out the possibility of harm,
clindamycin should only be used during pregnancy if clearly needed).3
The clinical experience includes studies on the adjunctive use of
clindamycin to prevent preterm labor and delivery, especially in
women with bacterial vaginosis,26 as well as an alternative for per-
ipartum group B Streptococcus prophylaxis in the presence of maternal
allergy to penicillins.27 A teratological study on lincosamides, including
clindamycin, suggested that the risk for major congenital anomalies
was not increased.28 This is in line with another cohort of 647 new-
borns that were exposed to clindamycin in the first trimester of
pregnancy.3,28
Pharmacokinetics: For clindamycin, pregnancy related changes in
body composition and weight, but also changes in alpha-1 acid glyco-
protein concentration and CYP3A4 activity matter (Figure 1).
Clindamycin is most often administered by intravenous route, but oral
administration is also possible because its absorption is rapid and
extensive with an estimated bio-availability of 87%.29 Clindamycin
distributes extensively in body fluids and tissues, including bone and
capsular tissue, but not the cerebrospinal fluid.30 It diffuses across the
placenta into the fetal circulation and appears in breast milk (breast
milk/maternal plasma ratio 0.08-3.1).25,30-35 The level of protein bind-
ing in non-pregnant humans ranges from 62% to 94% and binding
relates to the alpha-1 acid glycoprotein concentration.25 Clindamycin
is metabolized to the active N-demethyl (cytochrome p450 (CYP)3A4)
and sulphoxide metabolites and also some inactive metabolites. These
characteristics change throughout pregnancy. About 10% of the drug
is excreted in the urine as active drug or metabolites and about 4% in
the feces. The remainder is excreted as inactive metabolites. Its elimi-
nation half-life is about 2-3 hours in healthy, non-pregnant adults.3
At delivery and based on maternal plasma observations collected
in seven term pregnancies following iv administration (900 mg), the
mean estimated clearance was 10 L/h, the elimination half-life was
2.6 hours.25 After oral administration of a single dose of clindamycin
(450 mg, 2.5-6.5 hours before therapeutic abortion) in seven pregnant
women (10-22 weeks of gestational age), the maternal peak
concentration and the concentration at intervention were 5.16 (2.9-9)
and 1.77 (0.68-4.5) mg/L respectively. After repeated oral administra-
tion (450 mg.q8h, 4-20 doses, 4.6 [1.8-9] g, with the last dose
3.3-6.3 hours before therapeutic abortion), these maternal plasma
concentrations were 6.3 (4.2-10.4) and 2.84 (1.1-5.8) mg/L,
respectively.32
Four studies reported on the maternal-umbilical cord blood concen-
trations during either single or repeated clindamycin (450-900 mg) iv
administration.25,31-33 Because of the different doses applied and the
absence of clinical data on individual maternal weight, we used paired
maternal and cord blood clindamycin levels to calculate the fetal/
maternal ratio. Based on 33 paired observations extracted from the
individual articles, the mean ratio was 0.72 (SD 0.36). This ratio was
higher (P < .05) during repeated (n = 14, 0.8, SD 0.37) compared to
single (n = 19, 0.6, SD 0.31) dose administration, likely reflecting the
fact that some accumulation occurs as the fetal compartment behaves
as a deep compartment. Figure 2 provides an overview of the time-
concentrations points collected in maternal and umbilical cord blood
after single clindamycin (900 mg) administration in 14 cases as pooled
from two different studies.25,31 The pattern suggests that maternal-
fetal transfer is fast, but incomplete.34
Finally, we could only retrieve data on amniotic fluid disposition
in the earlier mentioned oral clindamycin study in women undergo-
ing termination of pregnancy.32 After oral administration of a single
dose of clindamycin (450 mg, 2.5-6.5 hours before the procedure)
in seven pregnant women (10-22 weeks of gestational age), the
amniotic fluid concentration was 0.02 mg/L at intervention. After
repeated oral administration (450 mg.q8h, 4-20 doses, 4.6
[1.8-9] g, last dose 3.3-6.3 hours before therapeutic abortion), the
amniotic fluid concentration was 0.82 (0.3-1.9) at intervention
(n = 5), or 1.07 (0.64-1.6) mg/L at delivery (n = 4).32 Similar to
cefazolin, the amniotic cavity seems also to behave as a deep com-
partment and the threshold concentrations (<0.5-4 mg/L) are not
always attained, be it that the target for S aureus (<0.25 mg/L) is
likely reached.
Clinical practice and efficacy: Clindamycin has been extensively
prescribed for several decades to prevent or treat infections during
pregnancy and in peripartum.3 The CDC recommended dosage of
900 mg.q8h iv to result in a rapid and steep decline of vaginal group B
Streptococcus colony counts (<5% of the colony counts) within the
first 2 hours after administration, similar to the decline after penicillin
administration.27 We could not retrieve data specific to the fetal sur-
gery setting.
2 | DISCUSSION
We provided an overview on observations on cefazolin and
clindamycin disposition, with specific emphasis on the deep compart-
ments relevant for antimicrobial prophylaxis during fetal surgery. As
both compounds have a relative low molecular weight (454.5 and
424.9 g/mol), with reduced pregnancy-related protein binding (albu-
min and alpha-1 glycoprotein respectively, Figure 1), passive placental
F IGURE 3 Simulation for the maternal plasma and the amniotic
fluid compartment in a pregnant patient with polyhydramnios, when
4 g cefazolin were administered with a second dose (4 g) 8 hours after
the first dose.20 X-axis = time (minutes); Y-axis = clindamycin
concentration (mg/L)
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diffusion occurs and results in relevant fetal exposure in the hours
after maternal administration.
In contrast, the amniotic fluid behaves for both drugs as a deep
compartment, with concentration-time profiles displaying a delayed
and much more blunted pattern compared to the maternal and fetal
plasma compartment. These concentrations are further diluted in the
presence of polyhydramnios. Along this deep compartment concept,
there is some accumulation during repeated administration, modeled
for cefazolin20 and observed for clindamycin.32
Although based on a limited number of observations, we hypoth-
esize that it is worth the effort to explore the potential clinical rele-
vance of the relative underexposure to antimicrobials in the amniotic
fluid, as this may be reflected in the pattern of maternal-fetal compli-
cations after fetal surgery. In a recent systematic review and
meta-analysis in this journal and based on 10 596 patients, maternal
complications were estimated to occur in 6.2% of fetoscopic and
20.9% of open fetal surgeries (serious in 1.7 and 4.5% respectively),
but any linkage with antimicrobial prophylaxis practices was not possi-
ble.36 Chorio-amnionitis or endometritis following an ex utero intra-
partum treatment procedure occurred in 4.13%, and in 1.45%
undergoing fetoscopic surgery, following PROM in 47.8 and 36.3% of
these cases, with two additional case descriptions of severe chorio-
amnionitis with maternal sepsis (one case following bipolar cord coag-
ulation, one case following fetoscopic laser photocoagulation).36 As
also mentioned by these authors, consistent, structured and prospec-
tive reporting on maternal complications using the existing registries
is needed to properly quantify maternal risks.36
Multidisciplinary reflections on the antimicrobial prophylaxis prac-
tices during fetal surgery are valuable as part of this need to quantify
maternal risks. This should combine fetal surgery expertise, knowl-
edge on microbiology and pharmacometric skills. Pharmacometric
skills cover both population pharmacokinetic and physiology-based
modeling as very powerful mathematical tools to generate knowledge.
Population PK models enable the analysis and interpretation of
dense, unbalanced or even sparse observations to explore covariates
in order to (partly) explain inter-individual variability (including preg-
nancy), to individualize dosing or explore scenarios.4 To illustrate its
potential relevance, we refer to the earlier reported simulations based
on the cefazolin dataset collected in maternal plasma and amniotic
fluid during fetal surgery.20 As illustrated in Figure 3, a second dose of
cefazolin (4 g.q8h) will result in attainment of the target MIC concen-
tration (2 mg/L) of cefazolin for S aureus in the amniotic cavity, even
in the setting of polyhydramnios.20 Alternatively, intra-amniotic injec-
tion can be considered, although there are no data yet on its safety.
The practice to inject antibiotics in the amniotic cavity exists at the
end of open fetal repair of spina bifida.11,12
Physiology-based PK (PB-PK) models are “exposure prediction”
models consisting of a multiple of differential equations that deter-
ministically simulate or predict drug movements in the body within a
physiologically realistic structure. In this structure, tissues and organs
are compartmentalized with knowledge of their size and composition.
The different compartments are interconnected through the
blood flow and arranged in a parallel circuit to reflect the circulatory
system. PB-PK modeling has moved to the front line as a promising
approach to ultimately predict the PK in pregnant women prior to ini-
tializing clinical trials. Such PB-PK model of renally cleared antimicro-
bials (cefazolin, cefuroxime, cefradine) has been described, and
contains an amniotic fluid compartment.5,37 Irrespective of the model
method applied, in vivo data are needed to further validate such esti-
mates as an intermediate step to confirm adequate antimicrobial
exposure as the final outcome step obviously is the incidence of infec-
tious complications.
In conclusion, but based on limited data on both pharmacokinet-
ics and efficacy and safety in this specific setting, we claim that fur-
ther studies should be designed by a multidisciplinary team (fetal
surgeons, clinical pharmacologists and microbiologists) to facilitate
efficient evaluation of antimicrobial prophylaxis in the specific field of
fetal surgery.
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